6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00642928
(ClinicalTrials.gov)
October 200721/3/2008Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease PatientsRandomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)Excessive Daytime Sleepiness;Parkinson's DiseaseDrug: Placebo;Drug: BF 2.649 5 mg;Drug: BF 2.649 10 mg;Drug: BF 2.649 20 mg;Drug: BF 2.649 40 mgBioprojetNULLCompleted18 YearsN/ABoth108Phase 2France
2EUCTR2007-003512-57-FR
(EUCTR)
24/08/200723/07/2007Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD) Excessive daytime sleepiness associated to Parkinson disease
MedDRA version: 9.1;Level: LLT;Classification code 10041014;Term: Sleepiness
MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease
Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649
Product Name: BF 2.649
Product Code: BF 2.649
BioprojetNULLNot RecruitingFemale: yes
Male: yes
130Phase 2France